| Identification | Back Directory | [Name]
AZTSBAWJROLRIQ-LESCRADOSA-N | [CAS]
135383-55-0 | [Synonyms]
AZTSBAWJROLRIQ-LESCRADOSA-N
Monomethyl auristatin E intermediate-7
(3R,4S,5S)-tert-Butyl 4-(((benzyloxy)carbonyl)amino)-3-hydroxy-5-methylheptanoate
tert-butyl (3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-3-hydroxy-5-methylheptanoate
tert-butyl (3R,4S,5S)-3-hydroxy-5-methyl-4-(phenylmethoxycarbonylamino)heptanoate
Heptanoic acid, 3-hydroxy-5-methyl-4-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, [3R-(3R*,4S*,5S*)]- (9CI) | [Molecular Formula]
C20H31NO5 | [MDL Number]
MFCD28386970 | [MOL File]
135383-55-0.mol | [Molecular Weight]
365.46 |
| Hazard Information | Back Directory | [Uses]
Monomethyl auristatin E intermediate-7 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs)[1]. | [References]
[1] Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. DOI:10.1158/0008-5472.CAN-14-1931 |
|
|